Stock listing

ASX:IMU Imugene Ltd Share Price

Home listing (ASX) of Imugene Ltd

Follow Imugene Ltd into a list and get an email when it puts out news.

Share price · ASX:IMU

$0.032 AUD +0.001 (+3.2%)

Close on Nov 20, 2026

Past year -89.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.031 – $0.032 AUDNov 20, 2026
Volume
802,833 sharesNov 20, 2026
Market cap
$17.73M AUDAt the close on Nov 20, 2026 · price × 554.1M shares outstanding
52-week range
$0.030 – $0.410 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$125,040 AUDMedian day 2.11M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Imugene Ltd logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:IMU · Home$0.032 AUD+0.001 (+3.2%)802,833$0.031$0.032$0.031$0.031Close on Nov 20, 2026
OTC:IUGNF$0.031 USD+0.002 (+6.9%)12,656$0.021$0.031$0.021$0.029Close on Nov 20, 2026
Frankfurt:ILA€0.018 EUR+0.001 (+2.9%)—€0.018€0.018€0.018€0.017Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:IMU · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.032+0.001+3.2%$0.031$0.032$0.031802,833
$0.031-0.002-6.1%$0.033$0.033$0.0312,344,992
$0.033-0.002-5.7%$0.035$0.035$0.0331,255,385
$0.035-0.001-2.8%$0.036$0.036$0.033803,725
$0.036+0.001+2.9%$0.035$0.036$0.034528,880
$0.035+0.001+2.9%$0.035$0.036$0.034750,930
$0.034-0.002-5.6%$0.036$0.036$0.0341,258,675
$0.036-0.002-5.3%$0.038$0.039$0.0361,391,764
$0.038+0.002+5.6%$0.036$0.039$0.0351,650,559
$0.036+0.001+2.9%$0.036$0.036$0.0331,475,944
$0.035+0.005+16.7%$0.030$0.036$0.0305,544,880
$0.030-0.003-9.1%$0.033$0.033$0.0305,928,012
$0.033-0.001-2.9%$0.033$0.034$0.033197,738
$0.034-0.001-2.9%$0.035$0.035$0.033707,327
$0.035-0.003-7.9%$0.037$0.037$0.0332,873,391
$0.038+0.003+8.6%$0.038$0.038$0.036898,785
$0.035-0.001-2.8%$0.037$0.037$0.035918,845
$0.036+0.001+2.9%$0.035$0.037$0.035911,004
$0.035-0.003-7.9%$0.036$0.037$0.0351,881,028
$0.038-0.001-2.6%$0.039$0.039$0.0352,122,778
$0.039+0.002+5.4%$0.037$0.039$0.0372,102,517
$0.037+0.001+2.8%$0.036$0.037$0.0354,194,902
$0.036+0.002+5.9%$0.035$0.036$0.0343,509,307
$0.034-0.002-5.6%$0.038$0.039$0.0338,242,493
$0.036+0.002+5.9%$0.034$0.036$0.0322,269,661
$0.034-0.002-5.6%$0.036$0.036$0.0343,119,300
$0.036-0.001-2.7%$0.037$0.037$0.0361,098,831
$0.037-0.002-5.1%$0.040$0.040$0.0374,031,117
$0.0390.0000.0%$0.040$0.042$0.0392,244,206
$0.039-0.003-7.1%$0.041$0.042$0.0391,833,594
$0.042+0.001+2.4%$0.041$0.043$0.0392,315,349
$0.0410.0000.0%$0.041$0.042$0.0394,284,215
$0.041-0.002-4.7%$0.046$0.046$0.0413,986,611
$0.043+0.006+16.2%$0.043$0.050$0.04319,537,971
$0.037-0.002-5.1%$0.039$0.039$0.0375,400,451
$0.039-0.003-7.1%$0.043$0.043$0.0395,211,887
$0.042-0.001-2.3%$0.043$0.044$0.0421,683,385
$0.043+0.002+4.9%$0.041$0.044$0.0411,048,439
$0.041-0.003-6.8%$0.045$0.046$0.0411,767,094
$0.0440.0000.0%$0.044$0.044$0.0422,229,255
$0.0440.0000.0%$0.044$0.046$0.0432,162,405
$0.044-0.003-6.4%$0.047$0.048$0.0443,479,990
$0.0470.0000.0%$0.048$0.049$0.0472,093,399
$0.0470.0000.0%$0.049$0.049$0.0462,229,871
$0.0470.0000.0%$0.048$0.049$0.0471,983,282
$0.047+0.001+2.2%$0.046$0.050$0.0453,910,667
$0.046-0.001-2.1%$0.047$0.049$0.0463,473,324
$0.047-0.006-11.3%$0.051$0.052$0.0476,238,952
$0.053-0.001-1.9%$0.055$0.055$0.0503,786,265
$0.054-0.004-6.9%$0.059$0.059$0.0543,206,030
$0.058-0.005-7.9%$0.062$0.062$0.0572,370,473
$0.063-0.002-3.1%$0.067$0.067$0.0625,130,624
$0.065-0.003-4.4%$0.066$0.067$0.0641,163,363
$0.068-0.001-1.4%$0.068$0.068$0.0651,535,518
$0.069+0.003+4.5%$0.067$0.069$0.0651,360,438
$0.066-0.002-2.9%$0.068$0.068$0.0651,064,652
$0.0680.0000.0%$0.067$0.070$0.0651,490,620
$0.0680.0000.0%$0.068$0.069$0.0661,822,847
$0.068-0.002-2.9%$0.071$0.071$0.0681,875,731
$0.070-0.001-1.4%$0.071$0.073$0.0701,459,276
$0.0710.0000.0%$0.070$0.072$0.0682,515,348
$0.071-0.002-2.7%$0.073$0.074$0.0702,965,581
$0.073-0.006-7.6%$0.079$0.080$0.0726,167,979
$0.079-0.003-3.7%$0.083$0.083$0.0792,485,415
$0.082-0.001-1.2%$0.084$0.084$0.082297,962
$0.0830.0000.0%$0.083$0.084$0.082740,121

Splits

3 splits since 2002 · ASX:IMU · every price before a split is adjusted for it

DayRatioWhat
1-for-34Consolidation
2-for-15Consolidation
1-for-5Consolidation
Ticker
ASX:IMU
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Imugene Ltd news

Imugene Ltd on 6ix

Sector
Health care
Industry
Biotechnology
News releases
57 in the last 12 months · 266 in all · newest Nov 20, 2026 · oldest 2016
Decks
54 decks · latest Jul 7, 2026

Where Imugene Ltd is listed

ListingExchangeCountryCurrency
ASX:IMU · Home listing · This pageASXAustraliaAUD
Stuttgart:ILAStuttgartGermanyEUR
OTC:IUGNFOTCUnited StatesUSD
Frankfurt:ILAFrankfurtGermanyEUR

Valuation

Price/book 2.0× against a median of 4.5×: 4th lowest of 8 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$21.40M AUD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.7×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Imugene Ltd · ASX:IMUUS$11.74MUS$14.16Mn/an/an/a2.0×n/a0.7×n/a
Genflow Biosciences PLC · LSE:GENFUS$12.06MUS$11.23Mn/an/an/a48.5×n/a0.0×n/a
BioCardia, Inc. · NASDAQ:BCDAUS$11.88MUS$10.22Mn/an/an/a14.2×n/a0.7×0.42
Xintela AB · OMXSTO:XINTUS$11.88MUS$11.81Mn/a39.8×n/an/an/an/an/a
Pluri Inc. · NASDAQ:PLURUS$11.85MUS$38.65Mn/a26.5×n/an/an/an/a0.53
Synlogic Inc · OTC:SYBXUS$11.76MUS$201,442n/an/an/a1.2×n/a0.0×0.50
Radiopharm Theranostics Limited · ASX:RADUS$11.59MUS$8.85Mn/a4.8×n/a0.7×n/a0.0×n/a
Aelis Farma SA · EURONEXT:AELISUS$11.55MUS$9.09Mn/a4.0×n/a4.5×−308.7%1.9×n/a
Simris Group AB Class B · OMXSTO:SIMRIS_BUS$11.54MUS$19.53Mn/a144×n/a154×n/a117×n/a
Dyadic International, Inc. · NASDAQ:DYAIUS$11.51MUS$12.03Mn/a3.9×n/an/a−226.9%n/a1.12
Psyence Biomedical Ltd. · NASDAQ:PBMUS$11.33MUS$4.18Mn/an/an/a0.9×n/a0.0×0.90
Median of the othersUS$11.68MUS$10.73M15.7×4.5×−267.8%0.0×0.53

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
0.23 AUD · Analysts' mean
EPS, year to Jun 2027
-0.055 · 2 analysts

Team and board

Officers

OfficerRole
Paul HopperExecutive Chairman

Board

DirectorRole
Paul HopperExecutive Chairman
Charmaine GittlesonNon-Executive Director
Jakob DupontNon-Executive Director
Kim DrapkinNon-Executive Director
Michael KotsanisNon-Executive Director

Events

QuarterResultsShare move
Quarter to Sep 30, 2025Dec 3, 2025−1.5%
Q4 2025Aug 25, 2025−8.8%
Quarter to Mar 31, 2025May 28, 2025−5.9%
Q2 2025Feb 27, 2025+2.8%
Quarter to Sep 30, 2024Nov 27, 2024+2.6%
Q4 2024Aug 30, 2024+15.3%
Quarter to Mar 31, 2024May 29, 2024−2.9%
Q2 2024Feb 28, 2024+4.3%
Quarter to Sep 30, 2023Oct 31, 2023 · Before open+2.4%
Q4 2023Aug 25, 2023 · Before open−2.8%
All 18 quarters
QuarterResultsShare move
Q3 2023Apr 28, 2023 · After close+4.0%
Q2 2023Feb 28, 2023 · After close0.0%
Q1 2023Nov 30, 2022+5.6%
Q4 2022Aug 31, 2022 · Before open+8.3%
Q3 2022Jun 1, 2022−12.8%
Q2 2022Feb 27, 20220.0%
Q4 2021Aug 30, 2021+20.3%
Q2 2021Feb 26, 2021−4.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck29 slidesJul 7, 2026
Investor Presentation (March 2026)Investor deck31 slidesMar 11, 2026
Technical Presentation (February 2026)Technical15 slidesFebruary 2026
Shareholder Meeting (November 2025)Shareholder meeting16 slidesNov 13, 2025
Shareholder Meeting (August 2025)Shareholder meeting6 slidesAug 20, 2025
Investor Presentation (July 2025)Investor deck37 slidesJul 16, 2025
Shareholder Meeting (January 2025)Shareholder meeting10 slidesJan 22, 2025
Shareholder Meeting (November 2024)Shareholder meeting18 slidesNov 14, 2024
Investor Presentation (September 2024)Investor deck32 slidesSeptember 2024
Azer-cel Webinar September 2024Conference14 slidesSeptember 2024
Show 50 decks
DeckKindSlidesDate
Investor Presentation (July 2024)Investor deck33 slidesJuly 2024
Bell Potter Emerging Leaders Conference 2024Conference28 slidesMay 2024
Investor Presentation (May 2024)Investor deck30 slidesMay 2024
JP Morgan Healthcare Conference 2024Conference35 slidesJan 10, 2024
Shareholder Meeting (November 2023)Shareholder meeting14 slidesNov 30, 2023
Shareholder Meeting (September 2023)Shareholder meeting17 slidesSep 28, 2023
Investor Presentation (August 2023)Investor deck30 slidesAug 18, 2023
Investor Presentation (July 2023)Investor deck38 slidesJul 20, 2023
NWR Healthcare Conference 2023Conference34 slidesMar 22, 2023
Non-Deal Roadshow (March 2023)Roadshow32 slidesMar 15, 2023
JP Morgan Healthcare Conference 2023Conference38 slidesJan 9, 2023
Shareholder Meeting (November 2022)Shareholder meeting15 slidesNov 17, 2022
Investor Presentation (November 2022)Investor deck31 slidesNov 15, 2022
Shareholder Meeting (November 2021)Shareholder meeting11 slidesNov 19, 2021
Investor Presentation (November 2021)Investor deck18 slidesNov 1, 2021
Investor Presentation (October 2021)Investor deck31 slidesOct 5, 2021
Investor Presentation (August 2021)Investor deck18 slidesAug 5, 2021
Investor Presentation (July 2021)Investor deck28 slidesJul 29, 2021
Investor Presentation (June 2021)Investor deck25 slidesJun 11, 2021
Investor Presentation (May 2021)Investor deck18 slidesMay 18, 2021
Shareholder Meeting (November 2020)Shareholder meeting14 slidesNov 24, 2020
Investor Presentation (November 2020)Investor deck31 slidesNov 24, 2020
Investor Presentation (November 2019)Investor deck31 slidesDec 2, 2019
Shareholder Meeting (November 2019)Shareholder meeting10 slidesNov 8, 2019
Investor Presentation (November 2019)Investor deck40 slidesNov 6, 2019
15th Bioshares Biotech Summit 2019Conference25 slidesJul 26, 2019
Investor Presentation (July 2019)Investor deck35 slidesJul 15, 2019
Planet MicroCap Showcase 2019Conference34 slidesMay 1, 2019
Investor Presentation (April 2019)Investor deck27 slidesApr 16, 2019
Investor Presentation (March 2019)Investor deck25 slidesMar 26, 2019
Investor Presentation (January 2019)Investor deck20 slidesJan 10, 2019
Shareholder Meeting (November 2018)Shareholder meeting12 slidesNov 13, 2018
Bioshares Biotech Summit 2018Conference16 slidesJul 27, 2018
Shareholder Meeting (July 2018)Shareholder meeting10 slidesJul 9, 2018
Investor Presentation (June 2018)Investor deck24 slidesJun 7, 2018
Investor Presentation (June 2018)Investor deck23 slidesJune 2018
Investor Presentation (January 2018)Investor deck34 slidesJan 9, 2018
Investor Presentation (November 2017)Investor deck32 slidesNovember 2017
Investor Presentation (October 2017)Investor deck36 slidesOctober 2017
Investor Presentation (July 2017)Investor deck40 slidesJuly 2017

This page holds 50 of 54 decks. Open Decks

Open Decks

Financings

RaiseDateIn US dollars
Convertible notes (New Notes)
Terms changed: convertible
Buyers: CVI Investments, Inc.
Nov 2, 2026
Convertible notes (TAR Notes)
Terms changed: convertible
Buyers: CVI Investments, Inc.
Nov 2, 2026
Private placement of fully paid ordinary shares
Closed: A$0.095 a share
Sep 1, 2026
Convertible notes (TAR Notes) and warrants
Closed: A$2.1M raised · Warrants at A$0.0664 for 60 months
Buyers: CVI Investments, Inc. ($2,100,000 worth of TAR Notes and 25,301,205 New Warrants)
Use of proceeds: Fund Cohort 2 and new Cohort 3 (BTKi) of its Phase 1b trial, plus general administrative and working capital
Aug 27, 2026US$1.49M
Private placement of new shares with attaching options
Announced: A$22.5M · A$0.33 a share · Warrants at A$0.43
Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26
Jul 16, 2025US$14.67M
Share purchase plan of new shares with attaching options
Announced: A$15M · A$0.33 a share · Warrants at A$0.43
Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26
Jul 16, 2025US$9.78M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue4.40M4.97M11.8M13.0M7.23M4.13M4.13M1.84M1.16M
Cost of revenue6.84M3.38M5.84M2.20M2.41M1.96M82.5K63.3K2.68K1.74K
Gross profit-6.84M4.40M4.97M9.57M10.6M5.27M4.05M4.06M1.84M1.16M
Research and development50.9M46.7M86.9M30.9M36.6M15.4M9.36M7.61M4.15M2.47M
Selling, general and administrative32.2M27.8M59.9M17.8M12.1M9.44M5.52M4.78M1.21M894.1K
Operating income-75.0M-70.9M-140.9M-51.3M-50.7M-25.7M-10.8M-12.4M-5.78M-3.69M
Depreciation and amortization6.84M3.38M5.84M2.20M2.41M1.96M82.5K63.3K2.68K1.74K
EBITDA-68.1M-67.6M-135.1M-49.1M-48.3M-23.7M-10.7M-12.3M-5.78M-3.68M
Interest expense125.5K162.5K478.4K27.5K13.6K5.02K5.03K6.11K00
Income before tax-107.3M-69.0M-154.3M-49.7M-50.5M-25.7M-14.6M-7.78M-5.77M-3.67M
Income tax-2.00M-4.04M-4.62M-11.7M-12.6M-7.23M-4.13M-4.13M-1.84M-1.16M
Net income-105.3M-69.0M-149.7M-37.9M-37.9M-18.5M-10.5M-7.78M-3.93M-2.51M
Earnings per share, basic-0.32-0.32-0.72-0.01-0.23-0.13-0.09-0.00-0.05-0.04

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents2.63M21.9M93.1M153.2M99.9M29.5M30.1M19.0M7.82M4.81M
Short-term investments2.08M1.44M-10
Receivables2.38M10.0M12.6M12.1M12.8M6.66M4.19M4.22M1.91M1.22M
Inventory4.41M-2.23M-4.22M-1.91M-1.22M
Current assets9.82M41.7M113.0M165.7M113.8M36.3M34.5M23.4M9.83M6.05M
Property, plant and equipment1.73M1.70M683.0K862.8K466.0K155.6K233.1K3.90K3.25K
Total assets23.0M83.6M151.4M197.1M147.6M71.8M65.2M30.8M16.9M12.7M
Accounts payable5.57M6.84M5.97M2.34M4.51M759.7K1.01M1.48M288.5K16.2K
Current liabilities14.0M22.2M29.3M6.08M7.42M4.46M2.90M2.42M438.2K297.5K
Long-term debt2.58M985.5K985.5K985.5K
Total debt6.30M10.7M2.19M553.5K673.4K271.0K69.3K1.11M
Total liabilities14.0M38.6M33.1M7.44M8.90M6.79M5.40M3.48M1.44M1.28M
Shareholders' equity9.01M45.0M118.3M189.6M138.7M65.0M59.8M27.3M15.5M11.4M
Shares outstanding326.1M218.7M208.5M6.28B165.8M137.2M119.8M3.58B77.6M61.4M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-44.9M-75.6M-101.7M-29.8M-30.7M-13.1M-10.1M-7.91M-4.51M-2.67M
Capital spending-5-14.5M-7.07M0-257.7K-5.45M-1.49M-128.4K-3.33K-2.03K
Free cash flow-44.9M-90.0M-108.8M-29.8M-30.9M-18.6M-11.6M-8.04M-4.51M-2.68M
Cash from investing-4.35M-12.7M-7.25M9.63K-414.2K-5.48M-1.52M247.4K-412.9K-2.34K
Cash from financing30.0M17.4M49.4M83.0M101.4M18.0M22.7M18.8M7.93M5.93M
Dividends paid-77.9M-6.01M-17.9M-20.9M0
Share buybacks-2.67M-1.32M-2.74M-5.04M-6.15M-125.6K-1.80M-1.44M-848.1K-320.7K
Change in cash-19.3M-71.2M-60.0M53.3M70.4M-619.7K11.1M11.2M3.01M3.23M

Open Financials

Filings

FilingDateTypeFiled with
Change of Director's Interest Notice x2 - KD & JDNov 20, 2026Ownership change noticeASX
Application for quotation of securities - IMUNov 19, 2026FinancingASX
Final Director's Interest Notice - LRNov 18, 2026Ownership change noticeASX
Notification of cessation of securities - IMUNov 18, 2026Notification letterASX
Imugene Receives $2.1M R&D Tax RefundNov 15, 2026FinancingASX
Director Resignation and Committee ChangesNov 10, 2026Management or board changeASX
Results of 2026 Annual General MeetingNov 10, 2026Meeting outcomeASX
AGM PresentationNov 10, 2026Other filingsASX
Imugene selected for Poster Presentation at 2026 ASH MeetingNov 4, 2026Operations updateASX
Positive amendments to Convertible NotesNov 2, 2026FinancingASX
Show 200 filings
FilingDateTypeFiled with
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Further Responses in azer-cel Phase 1b TrialOct 18, 2026Operations updateASX
Notification of cessation of securities - IMUOct 16, 2026FinancingASX
Application for quotation of securities - IMUOct 14, 2026FinancingASX
Application for quotation of securities - IMUOct 13, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormOct 8, 2026Meeting noticeASX
Dr John Le Gall appointed Chief Medical OfficerOct 6, 2026Management or board changeASX
azer-cel BTKi Cohort Reports new Complete & Partial ResponseOct 4, 2026Operations updateASX
Change of Director's Interest Notice - JDOct 1, 2026Ownership change noticeASX
Application for quotation of securities - IMUSep 8, 2026FinancingASX
Cleansing NoticeSep 1, 2026FinancingASX
Application for quotation of securities - IMUSep 1, 2026FinancingASX
Change of Director's Interest Notice x4Sep 1, 2026Ownership change noticeASX
Corporate Governance Statement and Appendix 4GAug 28, 2026Other filingsASX
Appendix 4E and Annual ReportAug 28, 2026Annual reportASX
Notice under section 708A(12C)(e) of the Corporations ActAug 27, 2026Notification letterASX
Notice of Initial Substantial Holding for IMUAug 27, 2026Ownership change noticeASX
Becoming a substantial holder for IMUAug 26, 2026Ownership change noticeASX
Notification regarding unquoted securities - IMUAug 26, 2026Other filingsASX
Notification of cessation of securities - IMUAug 26, 2026FinancingASX
Application for quotation of securities - IMUAug 25, 2026FinancingASX
Amendment of Convertible NotesAug 20, 2026FinancingASX
Results of Extraordinary General MeetingAug 18, 2026Meeting outcomeASX
Letter To ShareholdersAug 9, 2026Other filingsASX
Expiry Of Listed OptionsAug 5, 2026Other filingsASX
Final Director's Interest Notice - LCJul 31, 2026Ownership change noticeASX
Notification of cessation of securities - IMUJul 31, 2026Notification letterASX
Quarterly Activities/Appendix 4C Cash Flow ReportJul 30, 2026Quarterly reportASX
Third response in concurrent BTKi Cohort of azer-cel TrialJul 26, 2026Operations updateASX
$11.1 Million Placement Completed to Advance azer-celJul 6, 2026FinancingASX
New Complete Response in the Concurrent BTKi azer-cel CohortJun 30, 2026Other filingsASX
First Complete Response in Concurrent BTKi azer-cel CohortJun 29, 2026Other filingsASX
Azer-cel Granted FDA Fast Track Designation for CLL and MZLJun 8, 2026Operations updateASX
First Patient in BTKi Combination Cohort of azer-cel studyMay 27, 2026Other filingsASX
Azer-cel Data from CAR T naive cohort in ASCO 2026 abstractMay 21, 2026Operations updateASX
ProspectusMar 17, 2026Offer documentASX
$20M placement and SPP, convertible notes amendedMar 11, 2026FinancingASX
100% and 80% ORRs in Subset Indications in azer-cel studyMar 9, 2026Operations updateASX
Trading HaltMar 9, 2026Trading halt or suspensionASX
Half Yearly Report and AccountsFeb 25, 2026Interim reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 29, 2026Quarterly reportASX
FDA Supports Strategy Toward Registration for Azer-celDec 7, 2025GuidanceASX
Strategic Collaboration with JW TherapeuticsNov 26, 2025Operations updateASX
S&P DJI Announces September 2025 Quarterly RebalanceSep 5, 2025Other filingsASX
Final Share Purchase Plan AllotmentAug 28, 2025FinancingASX
Appendix 4E and Annual ReportAug 25, 2025Annual reportASX
Imugene Capital Raising PresentationJul 16, 2025FinancingASX
Imugene Completes $22.5M Placement and c.$15M SPPJul 16, 2025FinancingASX
Two Additional Complete Responses in azer-cel Ph1b trialJul 13, 2025Operations updateASX
Notice of Extraordinary General Meeting/Proxy FormMay 27, 2025Meeting noticeASX
Azer-cel Granted FDA Fast Track Designation in Blood CancerMar 18, 2025Operations updateASX
S&P DJI Announces March 2025 Quarterly RebalanceMar 7, 2025Other filingsASX
Imugene Granted India Patent for Oncolytic Virotherapy CF33Feb 26, 2025Other filingsASX
Imugene OnCARlytics Patent Allowance in ChinaFeb 25, 2025Other filingsASX
Azer-cel demonstrates two additional Complete ResponsesFeb 13, 2025Operations updateASX
Imugene Receives A$20 million for Convertible Notes IssuanceJan 28, 2025FinancingASX
Imugene Receives $11.7m R&D Tax RefundJan 10, 2025FinancingASX
First Australian Patient Dosed in Phase 1b azer-cel TrialJan 2, 2025Operations updateASX
Issuance of Convertible Notes & Warrants for up to $46mDec 23, 2024FinancingASX
Imugene Confirms Pending Receipt of c.$11m R&D Tax RefundDec 18, 2024Other filingsASX
onCARlytics Trial Doses First Patient in IT Combination ArmNov 10, 2024Other filingsASX
Imugene Opens First Australian Site for azer-cel TrialNov 7, 2024Other filingsASX
Complete Response in MAST Study Maintained Over Two YearsNov 4, 2024Other filingsASX
Imugene Receives Orphan Drug Designation for VAXINIASep 18, 2024Operations updateASX
Three Complete Responses in Azer-Cel Phase 1b TrialSep 1, 2024Operations updateASX
First patient dosed in Phase 1 bile tract cancer trialJul 9, 2024Operations updateASX
Imugene onCARlytics Doses First Patient in IV CombinationJun 23, 2024Other filingsASX
Imugene and Kincell Bio Announce Strategic PartnershipApr 15, 2024Acquisition or disposalASX
Bile Tract Cancer Study Opens after MAST High Dose ClearanceApr 14, 2024Operations updateASX
VAXINIA and HER-Vaxx featured at the AACR Annual MeetingApr 7, 2024Operations updateASX
Oncolytic Virotherapy CF33 Patent Granted in ChinaApr 3, 2024Other filingsASX
Imugene to present at 2024 Cholangiocarcinoma ConferenceApr 2, 2024Other filingsASX
Phase 1 onCARlytics Trial Advances to Combination ArmMar 10, 2024Operations updateASX
Phase 1 onCARlytics Trial Doses First Intravenous PatientFeb 14, 2024Other filingsASX
VAXINIA Phase 1 trial doses patients in higher dose cohortsJan 18, 2024Other filingsASX
Phase 1 CF33-hNIS Study Update - Positive Early SignalsJan 16, 2024Other filingsASX
Imugene and NeoImmuneTech to Improve Cancer TreatmentsDec 11, 2023Other filingsASX
New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUSDec 5, 2023Other filingsASX
Europe Patent to be Granted for PD1-Vaxx Cancer VaccineDec 5, 2023Operations updateASX
FDA Fast Track Designation Granted for VAXINIA Trial ProgramNov 27, 2023Operations updateASX
Azer-cel Hits Major Milestone in Phase 1b CAR T TrialNov 9, 2023Other filingsASX
Phase 1 CF33 VAXINIA Study Update - Positive Early SignalsNov 5, 2023Other filingsASX
Next cohort reached in IV arms of CF33-hNIS (VAXINIA) studyNov 1, 2023Operations updateASX
Imugene Phase 1 onCARlytics CD19 virus clinical trial opensOct 25, 2023Other filingsASX
Imugene B Cell & OV Platforms Featured at ESMO CongressOct 23, 2023Operations updateASX
Azer-cel FDA IND Transferred to ImugeneSep 27, 2023Other filingsASX
Imugene Closes SPP Raising $18.2 millionSep 24, 2023FinancingASX
Imugene PD1-Vaxx UpdateSep 11, 2023Other filingsASX
Imugene Receives Positive Feedback From FDASep 10, 2023Other filingsASX
VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1Sep 3, 2023Other filingsASX
S&P DJI Announces September 2023 Quarterly RebalanceSep 1, 2023Other filingsASX
Preliminary Final ReportAug 25, 2023ResultsASX
Imugene completes $35M Placement & Launches c.$30M SPPAug 17, 2023FinancingASX
Imugene Licenses Allogeneic CD19 CAR T Cell TherapyAug 15, 2023Other filingsASX
Imugene VAXINIA Trial clears Cohort 3 of IT MonotherapyAug 13, 2023Other filingsASX
Imugene CF33 Oncolytic Virus Study to be Showcased at SITCAug 2, 2023Other filingsASX
Imugene HER-Vaxx and CHECKVacc to be Featured at ESMOJul 24, 2023Other filingsASX
Imugene and RenovoRx CF33 Virotherapy Delivery CollaborationJul 20, 2023Other filingsASX
Imugene Oncolytic Virotherapy CF33 Patent Allowed in the USJul 19, 2023Other filingsASX
New Dose Escalation in Phase I Clinical Trial of CHECKvaccJul 6, 2023Other filingsASX
HER-Vaxx induced antibodies correlated with tumour reductionJun 29, 2023Other filingsASX
Imugene PD1-Vaxx patent extended to 2040Jun 28, 2023Other filingsASX
Imugene Advances VAXINIA MAST Trial to Next IV CohortsJun 8, 2023Other filingsASX
Imugene doses first combination patient in PD1-Vaxx trialMay 31, 2023Other filingsASX
FDA clears Imugene IND for onCARlytics first-in-class studyMay 18, 2023Other filingsASX
onCARlytics with ARTEMIS T cells show anti-tumour activityMay 17, 2023Other filingsASX
onCARlytics with Artemis T cells abstract presented at ASGCTMay 2, 2023Other filingsASX
Imugene receives $12.6m R&D tax refundApr 25, 2023Other filingsASX
Imugene Images and Follows CHECKVacc in TNBC PatientsApr 19, 2023Other filingsASX
First patients dosed in IT & IV cohort 3 of VAXINIA trialApr 4, 2023Other filingsASX
First Patients Dosed in Combination Study of VAXINIAMar 2, 2023Other filingsASX
Imugene PD1-Vaxx Immunotherapy Patent Granted in the USFeb 9, 2023Other filingsASX
Imugene VAXINIA trial advances to Combination CohortFeb 1, 2023Other filingsASX
Imugene Receives Vaxinia Ethics Approval in AustraliaJan 8, 2023Other filingsASX
CHECKVacc Data Presented at the 2022 SABC SymposiumDec 8, 2022Other filingsASX
First Patient Dosed in VAXINIA Intravenous Cohort 2Dec 4, 2022Other filingsASX
Imugene onCARlytics with Estrella ARTEMIS T Cells SITCNov 13, 2022Other filingsASX
Dose escalates In Phase I Clinical Trial of New Oncolytic ViNov 11, 2022Other filingsASX
Imugene onCARlytics with blinatumomab SITC presentationNov 10, 2022Other filingsASX
Europe Patent granted for iNKT Cell Therapy PlatformNov 6, 2022Other filingsASX
First patient dosed in VAXINIA intratumoral cohort 2Oct 30, 2022Other filingsASX
Preclinical trial of ALA iNKT therapy and IMU onCARlyticsSep 26, 2022Other filingsASX
First patient IV dosed in VAXINIA Phase 1 clinical trialSep 20, 2022Other filingsASX
OGTR grants VAXINIA DIR licence allowing trial expansionSep 19, 2022Other filingsASX
Prospectus for the issue of institutional placement optionsSep 16, 2022FinancingASX
IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENTSep 12, 2022FinancingASX
Imugene doses first patient in nextHERIZON Phase 2 trialSep 7, 2022Other filingsASX
Imugene Dose Escalates in Phase I Clinical Trial of VAXINIAAug 31, 2022Other filingsASX
Annual Report and Appendix 4EAug 30, 2022Annual reportASX
FIRST COHORT 3 PATIENT DOSED IN CLINICAL TRIAL OF CHECKVACCAug 9, 2022Other filingsASX
Imugene Presents New PD1-Vaxx Data at the 2022 WCLCAug 7, 2022Other filingsASX
Final HER-Vaxx Phase 2 Trial Overall Survival ResultsJun 26, 2022Other filingsASX
IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIALMay 17, 2022Other filingsASX
IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZONMay 9, 2022Other filingsASX
Clarification AnnouncementMay 3, 2022Other filingsASX
Termination of Supply AgreementMay 2, 2022Other filingsASX
Dose Escalation in Phase 1 Clinical Trial of CHECKvaccMar 23, 2022Other filingsASX
Clinical Trial of New Cancer Oncolytic Virotherapy VaxiniaMar 22, 2022Other filingsASX
Imugene HER-Vaxx Clinical Trial Collaboration with MerckMar 14, 2022Other filingsASX
Oncolytic Virotherapy CF33 Patent Granted in JapanJan 30, 2022Other filingsASX
PD1-Vaxx Clinical Trial Supply Agreement with RocheJan 28, 2022Other filingsASX
HER-Vaxx Immunotherapy Patent Granted in EuropeJan 27, 2022Other filingsASX
Imugene Receives $6.54 million R&D Tax IncentiveJan 6, 2022Other filingsASX
South Korea HERVaxx Patent GrantJan 5, 2022Other filingsASX
Imugene completes Phase 1a trial of immunotherapy PD1-VaxxJan 3, 2022Other filingsASX
FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXXDec 12, 2021Other filingsASX
Update on Clinical Trial of Oncolytic Virotherapy CHECKvaccDec 6, 2021Other filingsASX
S&P DJI Announces December 2021 Quarterly RebalanceDec 3, 2021Other filingsASX
Clinical Trial Supply Agreement with Merck KGaA and PfizerNov 15, 2021Other filingsASX
Investor Presentation Imugene Eureka TherapeuticsOct 31, 2021Other filingsASX
FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF CHECKVACCOct 20, 2021Other filingsASX
Imugene HER-Vaxx Immunotherapy Patent Granted in JapanSep 21, 2021Other filingsASX
S&P DJI Announces September 2021 Quarterly RebalanceSep 3, 2021Other filingsASX
Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New TrialsAug 31, 2021Other filingsASX
Appendix 4E and Full Year Statutory AccountsAug 30, 2021Annual reportASX
Phase 1 Clinical Trial Update of Immunotherapy PD1-VaxxAug 26, 2021Other filingsASX
Response to ASX QueryAug 23, 2021Explanation requestASX
Research partnership with Celularity for solid tumorsAug 4, 2021Other filingsASX
Prospectus for SPP and Placement Options OfferJul 29, 2021FinancingASX
Imugene completes $90 M placement and launches $5 M SPPJul 28, 2021FinancingASX
Appendix 4C - Quarterly ReportJul 23, 2021Quarterly reportASX
FDA IND APPROVAL OF NEW ONCOLYTIC VIROTHERAPY CHECKVACCJul 1, 2021Other filingsASX
Investor PresentationMay 17, 2021Other filingsASX
Prestigious Research Journal Publish HER-Vaxx Phase 1B DataApr 29, 2021Other filingsASX
Appendix 4C - quarterlyApr 23, 2021Quarterly reportASX
Imugene announces clinical milestone for HER-VaxxApr 20, 2021Other filingsASX
Imugene Oncolytic Virus Presentation at AACR 2021 MeetingApr 11, 2021Other filingsASX
Final Highest Dose in Phase 1 Clinical Trial of PD-VAXXApr 6, 2021Other filingsASX
S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021Other filingsASX
Imugene to Present HER-Vaxx Phase 2 Data at AACR21 MeetingMar 10, 2021Other filingsASX
Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX TrialFeb 11, 2021Other filingsASX
Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical TrialJan 20, 2021Other filingsASX
IMUGENE COMPLETES RECRUITMENT TO HER-VAXX PHASE 2 TRIALIMJan 6, 2021Other filingsASX
Imugene Enrols First Cohort of PD1-Vaxx Clinical TrialDec 16, 2020Other filingsASX
Imugene Receives $4.82 million R&D Tax IncentiveDec 10, 2020Other filingsASX
Imugene First Patient Dosed in PD1-VAXX Clinical TrialNov 30, 2020Other filingsASX
Imugene HER Vaxx shows positive Overall Survival in trialNov 22, 2020Other filingsASX
Imugene Receives FDA IND Approval for PD1-VAXX Trial in USANov 1, 2020Other filingsASX
Imugene Immunotherapy Combination Patent Granted in USOct 1, 2020Other filingsASX
Imugene Secures $5.7 million Option Underwriting AgreementSep 8, 2020Other filingsASX
Imugene Receives PD1-VAXX Ethics Trial Approval in USASep 3, 2020Other filingsASX
Appendix 4E & Annual Report to shareholdersAug 31, 2020Annual reportASX
Imugene Receives Third PD1-VAXX Ethics Trial ApprovalAug 20, 2020Other filingsASX
Imugene Receives Clinical Guidance from US FDA for VaxiniaAug 5, 2020GuidanceASX
Imugene Receives Second PD1-VAXX Ethics Trial ApprovalJul 16, 2020Other filingsASX
Imugene Receives Ethics Approval to Start PD1-VAXX TrialJul 13, 2020Other filingsASX
Imugene HER-Vaxx Phase 2 Clinical UpdateMay 3, 2020Other filingsASX
Imugene PD1-Vaxx Immunotherapy UpdateJan 27, 2020Other filingsASX
Imugene HER-Vaxx Immunotherapy Patent Granted in USJan 13, 2020Other filingsASX

This page holds 200 of 258 filings. Open Filings

Open Filings

Cap table

Built by 6ix from Imugene Ltd’s releases · as of Sep 1, 2026

Common shares
554,067,948
Fully diluted
554,067,948

Fully diluted

LineShares
Common shares554,067,948

Warrants and options

Lot
Warrants · A$0.0664 · expire about Aug 2031

Share count over time

CountShares
Nov 22, 2026554,067,948

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Charmaine GittlesonNon-Executive Director · Since at least Nov 12, 2026
Jakob DupontNon-Executive Director · Since at least Nov 12, 2026
Josep TaberneroPresident of ESMO · Nov 4, 2026 – Nov 11, 2026 · Past
Kim DrapkinNon-Executive Director · Since at least Nov 12, 2026
Lesley RussellNon-Executive Director · Nov 11, 2026 – Nov 11, 2026 · Past
Michael KotsanisNon-Executive Director · Since at least Nov 12, 2026
Paul HopperExecutive Chairman · Since at least Nov 12, 2026
Prasad S. AdusumilliDirector · Nov 4, 2026 – Nov 11, 2026 · Past
Yuman FongChair of the Department of Surgery · Nov 4, 2026 – Nov 11, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Imugene Ltd.